AU3158900A - Immunogens comprising a peptide and a carrier derived from h.influenzae protein - Google Patents
Immunogens comprising a peptide and a carrier derived from h.influenzae proteinInfo
- Publication number
- AU3158900A AU3158900A AU31589/00A AU3158900A AU3158900A AU 3158900 A AU3158900 A AU 3158900A AU 31589/00 A AU31589/00 A AU 31589/00A AU 3158900 A AU3158900 A AU 3158900A AU 3158900 A AU3158900 A AU 3158900A
- Authority
- AU
- Australia
- Prior art keywords
- immunogens
- peptide
- influenzae protein
- carrier derived
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9904412.5A GB9904412D0 (en) | 1999-02-25 | 1999-02-25 | Vaccine |
GBGB9904405.9A GB9904405D0 (en) | 1999-02-25 | 1999-02-25 | Vaccine |
GBGB9904408.3A GB9904408D0 (en) | 1999-02-25 | 1999-02-25 | Vaccine |
GB9904408 | 1999-02-25 | ||
GB9904412 | 1999-02-25 | ||
GB9904405 | 1999-02-25 | ||
GB9919260 | 1999-08-13 | ||
GBGB9919260.1A GB9919260D0 (en) | 1999-08-13 | 1999-08-13 | Vaccine |
PCT/EP2000/001457 WO2000050077A1 (en) | 1999-02-25 | 2000-02-22 | Immunogens comprising a peptide and a carrier derived from h.influenzae protein d |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3158900A true AU3158900A (en) | 2000-09-14 |
Family
ID=27451875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU31589/00A Abandoned AU3158900A (en) | 1999-02-25 | 2000-02-22 | Immunogens comprising a peptide and a carrier derived from h.influenzae protein |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1156825A2 (en) |
JP (1) | JP2002537354A (en) |
AR (1) | AR022758A1 (en) |
AU (1) | AU3158900A (en) |
CA (1) | CA2363118A1 (en) |
WO (1) | WO2000050077A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK200201741A (en) | 2002-11-12 | 2003-09-16 | Statens Seruminstitut | Vaccine comprises chimeric malaria proteins derived from Plasmodium falciparum genetically coupled to Plasmodium falcinarum Merozoite surface protein 3 |
AT413945B (en) * | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Use of a compound having a binding capacity to an antibody specific for the natural N-terminal AB42 sequence, for preparing a vaccine for preventing and treating Alzheimer's disease |
MY146566A (en) * | 2003-12-17 | 2012-08-30 | Wyeth Llc | Immunogenic peptide carrier conjugates and methods of producing same |
PL2336147T3 (en) * | 2003-12-17 | 2015-01-30 | Janssen Alzheimer Immunotherap | A beta immunogenic peptide carrier conjugates and methods of producing same |
BRPI0806463A2 (en) * | 2007-01-15 | 2011-09-06 | Glaxosmithkline Biolog Sa | fusion protein, nucleic acid sequence, vector, host cell, vaccine, use of a protein or nucleic acid or vectors, process for producing a fusion protein, and method for treating a cancer patient |
WO2011154878A1 (en) * | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
KR20190090775A (en) * | 2016-07-21 | 2019-08-02 | 백4올 피티이 리미티드 | Biofusion Proteins as Anti-malaria Vaccines |
US20240245190A1 (en) | 2023-01-19 | 2024-07-25 | Sharkninja Operating Llc | Identification of hair care appliance attachments |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8713240D0 (en) * | 1987-06-05 | 1987-07-08 | Proteus Biotech Ltd | Hormones |
SE466259B (en) * | 1990-05-31 | 1992-01-20 | Arne Forsgren | PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE |
BR9707819A (en) * | 1996-03-01 | 1999-07-27 | Novartis Ag | Peptide immunogens |
SE9601158D0 (en) * | 1996-03-26 | 1996-03-26 | Stefan Svenson | Method of producing immunogenic products and vaccines |
GB9720585D0 (en) * | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
-
2000
- 2000-02-22 JP JP2000600687A patent/JP2002537354A/en active Pending
- 2000-02-22 AU AU31589/00A patent/AU3158900A/en not_active Abandoned
- 2000-02-22 WO PCT/EP2000/001457 patent/WO2000050077A1/en not_active Application Discontinuation
- 2000-02-22 EP EP00909235A patent/EP1156825A2/en not_active Withdrawn
- 2000-02-22 CA CA002363118A patent/CA2363118A1/en not_active Abandoned
- 2000-02-25 AR ARP000100822A patent/AR022758A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000050077A9 (en) | 2001-08-16 |
WO2000050077A1 (en) | 2000-08-31 |
CA2363118A1 (en) | 2000-08-31 |
JP2002537354A (en) | 2002-11-05 |
AR022758A1 (en) | 2002-09-04 |
EP1156825A2 (en) | 2001-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU1951201A (en) | Peptide antigens | |
AU7358700A (en) | Dolastatin peptides | |
AU6173900A (en) | Peptide transport | |
AU6059699A (en) | Synthetic peptides, conjugation reagents and methods | |
AU6045900A (en) | Interaction-activated proteins | |
AU1191001A (en) | Plasminogen-like polynucleotides, polypeptides, and antibodies | |
AU7337400A (en) | B7-like polynucleotides, polypeptides, and antibodies | |
AU4281999A (en) | Peptide | |
AU1582401A (en) | Uteroglobin-like polynucleotides, polypeptides, and antibodies | |
AU3158900A (en) | Immunogens comprising a peptide and a carrier derived from h.influenzae protein | |
AU7335400A (en) | Attractin-like polynucleotides, polypeptides, and antibodies | |
IL141330A0 (en) | Dcr5, a bmp-binding protein and aplications thereof | |
AU2452301A (en) | Protein methylarginine-specific antibodies | |
AU1999999A (en) | Contryphan peptides | |
AU6127498A (en) | Msh-receptor subtype selective cyclic peptides | |
AUPO957397A0 (en) | Transporter protein | |
AU1356401A (en) | Follistatin-related protein zfsta4 | |
AU1595299A (en) | A carboxy-terminal brca1 interacting protein | |
AU4778600A (en) | Novel polypeptide | |
AU2094299A (en) | Wip, a wasp-associated protein | |
HK1014964A1 (en) | Somatostatin peptides. | |
GB9908920D0 (en) | Peptide | |
AU1552800A (en) | Coupled peptides | |
AU2109200A (en) | Polypeptide | |
AU2002500A (en) | Novel protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |